Kesimpta is used for the treatment of MS (Multiple Sclerosis), CIS (Clinically Isolated Syndrome), Active Secondary Progressive disease and relapsing remitting disease in adults.
MS or multiple sclerosis is what Kesimpta is most commonly used for but it's also used for the other above listed conditions.
MS or multiple sclerosis is a condition where the immune system is overactive and it mistakenly attacks the myelin sheath which is the covering over the nerves.
The condition CIS or clinically isolated syndrome also involves the immune system attacking the myelin sheath.
Kesimpta also known as ofatumumab is a fully human monoclonal antibody to CD20, which appears to provide rapid B-cell depletion.
And under the brand name Kesimpta, it is approved for the treatment of multiple sclerosis in the United States as well as in the European Union and other regions.
A new trial found that Kesimpta consistently beat Aubagio in sending MS into remission, regardless of patient race/ethnicity.
The trial also involved people with relapsing-remitting MS.
Kesimpta is an FDA approved medicine that is used to slow the progression and risk of relapses for specific forms of relapsing multiple sclerosis (MS).
Kesimpta is a once a month injection given under the skin (subcutaneously) that you can self-administer in your own home.
Common side effects of Kesimpta include injection-site reactions, such as redness, pain, itching and swelling at the injection site as well as injection-related reactions, such as fever, headache, muscle pain, chills and tiredness.
Kesimpta is not a chemotherapy drug, but it is an immunosuppressant.
Chemotherapy works by killing rapidly multiplying cells in the body.
The cost for Kesimpta (20 mg/0.4 mL) subcutaneous solution is around $9,208.00 for a supply of 0.4 milliliters, depending on the pharmacy you visit.
If you have ever had HBV infection, the HBV may become active again during or after treatment with KESIMPTA.
Hepatitis B virus becoming active again (called reactivation) may cause serious liver problems, including liver failure or death.
You should not take KESIMPTA if you have active hepatitis B liver disease.
As for long term use of Kesimpta and it's safety, the long-term Kesimpta use was found to be well-tolerated and there were no unexpected safety signals reported.
Overall adverse event (AE) and serious AE rates after six years of Kesimpta treatment were consistent with the core Phase III trials and the extension study.